BAXTER INTERNATIONAL INC (BAX) Stock
BAX has an Alpha Score of 39 out of 100 (weak), computed on Nov 1, 2026 from 3 of 4 sub-scores. 14 members of Congress disclosed 58 trades in BAX since 2014: 31 purchases and 27 sales, most recently Lisa McClain (sale, Oct 31, 2025). 5 of the hedge funds AlphaScala tracks reported BAX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $103.56M.
What is BAX's Alpha Score?
How it works →Alpha Score of 39 reflects weak overall profile with weak momentum, moderate value, poor quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 1, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded BAXTER INTERNATIONAL INC (BAX)?
Most recent: Lisa McClain (sale, Oct 31, 2025); records start Nov 5, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Lisa McClain R-MI · House | 2025-10-31 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-09-25 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-08-04 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-07-22 | purchase | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-05-15 | purchase | $1k – $15k |
| Debbie Wasserman Schultz D-FL · House | 2024-11-18 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all BAX political trades →Which hedge funds own BAX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 4.86M | $103.56M | +114% |
| Citadel Ken Griffin | 223K | $4.75M | -83% |
| Bridgewater Associates Ray Dalio | 17K | $369.8K | +8% |
| D.E. Shaw David Shaw | 16K | $338.4K | +48% |
| Millennium Management Israel Englander | 10K | $214.9K | -99% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are BAX's key statistics?
Key statistics as of Oct 25, 2026
How does BAX's valuation compare with the Healthcare sector?
| Metric | BAX | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -9.27% | 4.31% | 164 |
| Return on equity | -16.60% | 5.47% | 185 |
| Dividend yield (payers) | 3.22% | 1.59% | 55 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 7, 2026). P/E excludes loss-making companies.
BAX price chart
Powered by TradingViewWhat does BAXTER INTERNATIONAL INC do?
Baxter International Inc. is a multinational healthcare company headquartered in Deerfield, Illinois, founded in 1931. It provides a broad portfolio of essential medical products and therapies focused on treating chronic and acute conditions in hospital and renal care settings. The company operates through key segments including Medical Products and Therapies, which encompass advanced surgery technologies to enhance surgical techniques, infusion therapies with sterile intravenous solutions, infusion systems and devices, and parenteral nutrition; Healthcare Systems and Technologies, offering smart bed systems, patient monitoring and diagnostic tools, respiratory health devices, and surgical equipment; and Pharmaceuticals, producing inhaled anesthetics and generic injectable pharmaceuticals for pain management, critical care, anti-infection, and oncology. These offerings support acute care, nutritional support, and surgical interventions worldwide, serving healthcare providers with innovative solutions for patient care across Americas, EMEA, and Asia-Pacific regions. Baxter International Inc. plays a vital role in advancing hospital-based care and connectivity solutions.